database > company
Tianyin Pharmaceutical (TPI)
Biotech Specialty Pharma
Unionsun Yangkuo Plaza South Renmin Rd.
Chengdu, 610041 China
phone:+86.28.8551.6696
fax:+86.28.8551.6676
Symbol TPI
Exchange NYSE
Founded 1994
Employees 1365
www.tianyinpharma.com
Research Sector Biotech Specialty Pharma
Summary Description
Produces branded generics, chinese herbal medicine and other pharmaceuticals.
Management
Guoqing Jiang, MD, Chairman & CEO; James Jiayuan Tong, MD PhD, CFO & Chief Business & Development Officer; Tao (Victor) Yang, Chief Operating Officer
Ownership
Financials Mkt Cap :22
* numbers in thousands
 

Keywords
generics, herbal medicine, Cardiology, Allergy, Gastroenterology, Immunology, Audiology, Neurology, Orthopedics, Pediatrics



Comment | Printable Version | Modify profile |
Updated: May 22, 2013

Description
TPI is engaged in research, development, manufacturing, marketing and sale of patented biopharmaceutical, modernized TCMs, branded generics and other pharmaceuticals. It has three state-of-the-art manufacturing facilities and an extensive nationwide sales and distribution network throughout China.
Products / Services
TPI manufactures and markets a portfolio of 56 products, of which 23 are listed in the highly selective National Medicine Catalog of the National Medical Insurance program, 7 are included in the essential drug list of China. The best selling products: Ginkgo Mihuan for stroke and other cardiovascular conditions; Apu Shuangxin for inflammation and rheumatism; Azithromycin for bacterial infections; Xuelian Chongcao for immunity and sexual function; Qingre Jiedu for viral infections, H1N1 and influenza. These products totaled $10.1 million, representing 40% of most recent 2nd quarterly revenues ending 12/31/10.
Technology / Differentiation
TPI employs a collaborative partnership model for its R&D which has proven cost effective, efficient and with a shorter development cycle time. It has 10 products in the product pipeline pending SFDA approval. TPI has established R&D collaboration partnerships with some of the most prestigious research and development institutions in China, including China Pharmaceutical University, Sichuan University-affiliated West China Center of Medical Sciences, and Shaanxi University of Chinese Medicines.
Market / Customers
TPI\\\\\\\'s hospital coverage has currently expanded over 880 hospitals in China.
Strategy
Build its distribution and to add additional products to its portfolio both developed from the internal pipeline and provided by other manufacturers. It is also seeking to develop its international front to provide its products to the global markets.
Revenue / Funding
Fiscal year 2010 revenues grew 69% and Net Income by 71% from 2009. The Company is profitable and has $31 million in cash reserves as of March 1, 2011. Market Cap of $84 million.